logo

For the Inventor, By the Inventor

Abingdon, United Kingdom

Brian William Dymock

This inventor holds 20 USPTO granted patents, plus 1 CIPO patent, primarily in Cancer Therapeutics. Top assignees: Cancer Research Technology Limited, The Institute of Cancer Research, Vernalis &r&d) Ltd.. Active years: 2007-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian William Dymock. Retrieved from https://idiyas.com/inventor/brian-william-dymock

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20

% Patents Active = 40.0


Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 99(Granted Patents)


Location History:

  • Cambridge, GB (2007)
  • Abingdon, GB (2009 - 2014)
  • Abington, GB (2010 - 2017)
  • Singapore, SG (2012 - 2019)
  • Great Abington, GB (2019 - 2022)

Company Filing History:

goldMedal13 out of 269 
 
Cancer Research Technology Limited
 patents
silverMedal11 out of 24 
 
The Institute of Cancer Research
 patents
bronzeMedal8 out of 68 
 
Vernalis &r&d) Ltd.
 patents
4. 7 out of 7 
 
Vernalis (Cambridge) Limited
 patents
5. 4 out of 8 
 
Cti Biopharma Corp.
 patents
6. 2 out of 3,978 
 
Novartis Ag
 patents
7. 1 out of 1 
 
Institute of Cancer Research of Royal Cancer Hospital
 patent
8. 1 out of 857 
 
National University of Singapore
 patents
9. 1 out of 1 
 
The Institute of Cancer
 patent
10. 2 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 2007-2022

Loading Chart...
Loading Chart...
Areas of Expertise:
Isoxazole Compounds
HSP90 Inhibitors
Pyrazole Compounds
Cancer Treatment
Thieno[2,3-d]pyrimidines
Heat Shock Proteins
Selective Anti-Cancer Compounds
Acid Addition Salts
Hydrates
Polymorphs
Formulations
20 patents (USPTO):Explore Patents
1. 11234987 - Isoxazole compounds as inhibitors of heat shock proteins (2022-02-01),
2. 10413550 - Isoxazole compounds as inhibitors of heat shock proteins (2019-09-17),
3. 10308631 - Selective anti-cancer compounds (2019-06-04),
4. 9718793 - Isoxazole compounds as inhibitors of heat shock proteins (2017-08-01),
5. 9624242 - 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2017-04-18),
6. 9062074 - (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt (2015-06-23),
7. 8987243 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt (2015-03-24),
8. 8980873 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt (2015-03-17),
9. 8642594 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2014-02-04),
10. 8507480 - Isoxazole compounds as inhibitors of heat shock proteins (2013-08-13),
11. 8487095 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-iso-propyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2013-07-16),
12. 8450310 - Isoxazole compounds as inhibitors of heat shock proteins (2013-05-28),
13. 8163747 - Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms (2012-04-24),
14. 7820658 - Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors (2010-10-26),
15. 7803831 - 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer (2010-09-28),

Title: Innovations and Contributions of Brian William Dymock

Introduction: Brian William Dymock is a notable inventor based in Abingdon, GB, recognized for his significant contributions to the field of pharmaceuticals and cancer research. With a prolific portfolio of 20 patents, Dymock has focused on developing innovative compounds aimed at targeting heat shock proteins, which play a crucial role in cancer treatment.

Latest Patents: Among his recent patents, Dymock has developed isoxazole compounds that function as inhibitors of heat shock proteins, specifically targeting HSP90 activity. These isoxazoles are designed to treat various cancers and involve complex molecular structures. The patents detail compounds formulated with various aryl and heteroaryl radicals, divalent C-Calkylene, and other radical components, showcasing Dymock's expertise in medicinal chemistry and the molecular intricacies of drug design.

Career Highlights: Dymock has lent his expertise to prominent institutions, including Cancer Research Technology Limited and The Institute of Cancer Research. His role in these organizations has facilitated advancements in cancer therapeutics, solidifying his impact in the research community.

Collaborations: Throughout his career, Dymock has collaborated with notable colleagues such as Martin James Drysdale and Edward McDonald. These partnerships have been instrumental in driving innovative research initiatives and developing promising treatment options for cancer.

Conclusion: Brian William Dymock's innovative work in isoxazole compounds exemplifies the vital role of inventors in advancing medical science. His contributions to the field not only demonstrate his commitment to cancer research but also highlight the importance of collaboration in achieving significant breakthroughs. With a total of 20 patents to his name, Dymock continues to influence the landscape of pharmaceutical research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…